What Biotimize does

Biotimize is a Brazilian biopharmaceutical Contract Development and Manufacturing Organization (CDMO) and the first of its kind operating in Brazil and South America. The company provides end-to-end development services from cell line development through analytical method validation, formulation, and non-clinical material production, serving biopharmaceutical companies, biotechnology startups, universities, research institutions, clinical research organizations, and government entities. Its technology platform spans mammalian cell expression (CHO cells achieving approximately 5 g/L recombinant protein), microbial systems (E. coli, yeast), and viral vector production, all built on single-use infrastructure at a GLP-certified facility in Piracicaba, São Paulo. Biotimize holds exclusive access in Brazil to Berkeley Lights' Beacon optofluidic platform, which reduces cell line development timelines from months to weeks.

The company generates revenue through project-based, quote-priced CDMO contracts covering pre-clinical and clinical-stage development work. Pricing is not publicly disclosed and is tailored to each project's scope, development stage, and partner requirements. The GLP-certified R&D Center (inaugurated March 2024) currently supports non-GMP services, while a 20,000+ m² GMP production facility is under construction to enable Phase 1-3 clinical and commercial batch production compliant with ANVISA, FDA, EMA, and TGA standards. Biotimize was established in partnership with Sthorm in early 2023 following a $30 million Series A round announced in September 2022. The company operates with 11-50 employees under founder-CEO Fernando Barbosa and is positioning itself to address the structural dependency of Brazil and Latin America on imported biologics by offering local infrastructure that can reduce development costs by up to 50% versus international CDMO alternatives.

Name

Biotimize

Legal name

Biotimize

Website

https://biotimize.com.br

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

Biotimize is Brazil's first biopharmaceutical CDMO, offering end-to-end cell line development, process development, and analytical services to biopharma companies, biotech startups, universities, and government entities from its GLP-certified facility in Piracicaba, São Paulo.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Contract Development and Manufacturing (CDMO)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

akta.pro secondary industries

Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)

Keywords

• Biopharmaceutical CDMO services
• Cell line development
• Bioprocess engineering
• Contract manufacturing organization
• Biological drug development

Headquarters

HQ city

Piracicaba

HQ country

Brazil

HQ region

Latin America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Infrastructure, Personnel, Operations, Marketing or Sales

Revenue model

1. Contract Development and Manufacturing Services: Biotimize generates revenue through contracted CDMO services for biopharmaceutical development and manufacturing. Services include cell line development, process development (upstream/downstream), analytical testing, non-GMP and GMP production, and formulation development. Revenue is project-based with fees aligned to development stages from pre-clinical through clinical batch production.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Biotimize operates as a Contract Development and Manufacturing Organization (CDMO) for biopharmaceuticals, providing personalized biotechnology and bioprocess engineering-based services. The company offers end-to-end production across bacteria, yeast, mammalian cells, and viral vectors, including cell line development, upstream and downstream process development, analytical method development, formulation, and non-clinical material production using single-use technology under GLP certification, with a GMP facility under construction.

Differentiator

Problem solved

Functional benefit

Brands

• BTaas: Biotimize's biotechnology as a service offering providing personalized bioprocess engineering-based services.

Products and services

• Biopharmaceutical CDMO Services (BTaas - Biotechnology as a Service) Contract Development and Manufacturing services for biopharmaceutical companies covering end-to-end production from cell line development through upstream and downstream process development, analytical method development and validation, formulation, and non-clinical material production across mammalian cells (CHO, ~5 g/L), bacteria (E. coli), yeast, and viral vectors, with single-use technology throughout production, purification, and fill-finish.
• GLP R&D Center Laboratory Services GLP-certified laboratory services for pre-clinical material production and translational development, providing the regulatory-grade basis for generating reliable pre-clinical data for submissions to ANVISA, FDA, EMA, and TGA. Targeted at universities, research institutions, biotechnology startups, and pharmaceutical companies needing pre-clinical and clinical-stage development infrastructure.

Quantifiable outcome

• Reduced development costs by up to 50%
• +2 more outcomes

Named customers2 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core and minor.

• PQE GroupcoreImplementation/ SI/ Consulting PartnerPartnership to develop conceptual, basic, and executive projects for the CDMO facility. PQE Group is an ISO 9001 certified technology solutions and compliance consulting services company with global capabilities. They are developing the complete facility design including R&D Center (GLP) and CDMO (GMP) in approximately 3,000 m² space.
• Sail for HealthcoreStrategic or Co-development PartnerStrategic partnership to strengthen Biotimize's mission and create bridges between Brazil and global innovation ecosystems. Together positioning Brazil as a developer and producer of advanced therapies rather than just a consumer, with focus on contributing solutions to Latin America and the Global South.
• PHP BiotechcoreStrategic or Co-development PartnerDevelopment partnership for Pepcrotament, an innovative anticancer nanobody. Biotimize initiated production across bacteria, yeast, and mammalian cells to determine optimal expression platform. PHP Biotech's Chairman noted that working with a locally established entity enabled good communication and flexibility.
• GTH-B (WHO Global Training Hub for Biomanufacturing)minorOthersParticipation in WHO's Global Training Hub for Biomanufacturing program held in South Korea. Biotimize researcher Bruna Campos attended the 2022 Introductory Training Course for Standard Practices (GxP), gaining knowledge in international quality standards for vaccine and biomedical product development.
• Clinergy HealthminorStrategic or Co-development PartnerEcosystem partner listed as part of Biotimize's broader innovation network supporting the mission to strengthen Brazil's Health Economic-Industrial Complex.
• ViralCureminorStrategic or Co-development PartnerEcosystem partner in the Sthorm network focused on combining impact projects with strategic people aligned with democratizing access to science and health.

Scale indicators7 records

Recent moves10 records

Expansion highlights5 records

Broad incumbents

• Lonza Group: Global mammalian and microbial biologics CDMO leader offering end-to-end development and manufacturing services. Comparable as the benchmark full-service CDMO that Biotimize's end-to-end mammalian platform competes against for biotech and pharma customers.
• Catalent: Large diversified CDMO with biologics, cell therapy, and fill-finish capabilities. Comparable as an established incumbent offering overlapping biologics development and manufacturing services to global pharma customers.
• WuXi Biologics: China-based global biologics CDMO with end-to-end mammalian cell culture and viral vector services. Directly comparable in scope (CHO-based recombinant proteins, viral vectors, fill-finish) but at vastly greater scale and geographic reach.
• Samsung Biologics: Korean mega-CDMO with large-scale mammalian biologics manufacturing and recent viral vector expansion. Comparable end-to-end biologics CDMO positioning and similarly emerged from a regional base targeting global pharma clients.
• Charles River Laboratories: Global CRO/CDMO with biologics and cell therapy manufacturing services alongside discovery/preclinical offerings. Comparable as a broader life-sciences services platform with overlapping biopharmaceutical CDMO capabilities.

Direct peers

• AGC Biologics: Mammalian and microbial CDMO offering cell line development, process development, and GMP manufacturing. Closest comparable in modality mix (CHO/microbial/viral vectors) and end-to-end service model.
• Rentschler Biopharma: Germany-based CDMO focused on mammalian cell culture biologics, including cell line development and GMP production. Comparable mid-sized pure-play biologics CDMO with similar end-to-end service offering.

Regional players

• Bio-Manguinhos / Fiocruz: Brazilian government-affiliated biomanufacturer producing vaccines and biologics for the public health system. Direct Brazilian comparable addressing the same localization gap, though focused on vaccines and government supply rather than commercial CDMO services.
• Cristalia: Major Brazilian pharmaceutical manufacturer with biologics and biosimilars activities. Comparable as a Brazilian-headquartered biopharma operator; appears as a Biotimize website partner and represents the type of regional customer Biotimize serves.
• Eurofarma: Large Brazilian pharmaceutical company with growing biologics and biosimilars pipeline. Comparable as a LATAM-headquartered biopharma company that could anchor demand for Biotimize's CDMO services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/biotimize

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biotimize